Proventa’s Weekly Round-up – 29/11/19

December 2, 2019
In ,

After a short (long) absence due to one (the only) editor’s work at Proventa’s events in Boston, we’re back with your regular take on the week’s pharmaceutical events. This week, the headlines are variations on older themes: Novartis has agreed to pay more than £9 billion in cash for The Medicines Company, a deal approved by both companies’ boards; in the UK the NHS has been found to be running dangerously short of several life-saving drugs; and documents on the US-UK free trade negotiations have shown Trump reps “pushing hard” for the UK to create pro-US pricing reforms. 

NOVARTIS PAYS $9.7 BILLION FOR THE MEDICINES COMPANY – Novartis is paying $9.7 billion in cash for The Medicines Company, with the Swiss giant adding cholesterol drug Inclisiran to its roster to help patients lower the risk of cardiovascular issues. Novartis requires the drug to perform well in order to generate a satisfactory return from the deal: while some have expressed doubts, the drug’s apparent freedom from toxicities found in similar therapies is an important factor in future success. 

NHS LACKING SUPPLIES FOR SEVERAL LIFE-SAVING MEDICINES – Important medicines for conditions including cancer, heart conditions and epilepsy are running out within the NHS, a leaked document recently stated. The scale of the shortage has been described as “unprecedented”. 

U.S. REPS “PUSHED U.K. HARD” ON DRUG PRICING REFORMS – A leaked document has shown that Trump administration representatives have “pushed hard” for U.S.-supporting price reforms during free trade negotiations. The issue is particularly hot due to a lack of drug pricing-related issues featured in the Conservative Party manifesto, published ahead of the upcoming general election. The Conservative Party has denied the claims as “a conspiracy theory”. 

In other news: 


ViGeneron developing next-generation eye gene therapies

New computational model accurately identifies essential cancer genes for drug development

Clinical Trials

Keytruda potentially useful with prostate cancer “super responders”

Astrazeneca’s Imfinzi IO drug granted fast review for new lung cancer use


New technique could aid in creating uniform nanoparticles for drug delivery

That’s all for this week. See you next Friday.

Joshua Neil, Editor
Proventa International